Personal Injury Resources

A look at how Wall Street and the FDA dance with drugs like Vioxx.

The FDA has had a full plate with problems and issues, and now becoming almost entirely unpredictable can be thrown in on the list of problems. It wasn't that the FDA was ever fully predictable, but after recent drug and product recalls it has to make you wonder if they are becoming a Doubting Thomas. Bausch & Lomb's (BOL-NYSE) recent lens cleaner ReNu With MoistureLoc withdrawal, Merck's (MRK-NYSE) Vioxx woes, and even the Biogen-Idec (BIIB-NASDAQ) and Elan (ELN-NYSE/ADR) withdrawal of Tysabri are possibly ALL contributors to Neurocrine's woes this morning as it may be entirely possible that the FDA may be playing purely a defensive game.

Related Products: Visit our store

Read more from this blogger: Evaluating the Implosion in Neurocrine